,for, Item ID-
  • #1255995
  • CLIAWAIVED INC #WF-WV01P0002

Respiratory Test Kit WELLlife™ COVID-19 / Influenza A&B 25 Tests

TEST KIT, COVID-19 A&B WELL LIFE 1POS/1NEG (25/BX)

No Image

Features

  • The WELLlife™ COVID-19 / Influenza A&B Test Control Kit is For use under an Emergency Use Authorization (EUA) only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
  • The WELLlife™ COVID-19 / Influenza A&B Test Control Kit is intended for in vitro diagnostic use in quality control testing with the WELLlife™ COVID-19 / Influenza A&B Tes
  • The WELLlife™ COVID-19 / Influenza A&B Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
  • More …
  Log In to Order
or

Product Specifications


Features
  • The WELLlife™ COVID-19 / Influenza A&B Test Control Kit is For use under an Emergency Use Authorization (EUA) only: https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
  • The WELLlife™ COVID-19 / Influenza A&B Test Control Kit is intended for in vitro diagnostic use in quality control testing with the WELLlife™ COVID-19 / Influenza A&B Tes
  • The WELLlife™ COVID-19 / Influenza A&B Test is a lateral flow immunochromatographic assay intended for in vitro rapid, simultaneous qualitative detection and differentiation of influenza A and influenza B nucleoprotein antigens and SARS-CoV-2 nucleocapsid antigen directly from anterior nasal swab specimens of individuals with signs and symptoms of respiratory infection consistent with COVID-19 within the first five (5) days of symptom onset when tested at least twice over three days with at least 48 hours between tests
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, that meet the requirements to perform moderate, high or waived complexity tests
  • This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation
  • Positive results do not rule out bacterial infection or co-infection with other viruses
  • All negative results should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management
  • Negative results do not rule out influenza or SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions such as isolating from others and wearing masks
More Information

Frequently Viewed Together